Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms
Authors:
- 28 September 2016
- journal article
- letter
- Published by Springer Nature in Leukemia
- Vol. 31 (1) , 246-248
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for YouCurrent Hematologic Malignancy Reports, 2016
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic LeukemiaCancer Discovery, 2016
- The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell LymphomaClinical Cancer Research, 2016
- Chimeric Antigen Receptor T Cells for Sustained Remissions in LeukemiaNew England Journal of Medicine, 2014
- Current concepts in the diagnosis and management of cytokine release syndromeBlood, 2014
- Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging TherapiesThe Cancer Journal, 2014
- Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic LeukemiaScience Translational Medicine, 2014
- Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell LymphomaNew England Journal of Medicine, 2013
- Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2013
- T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced LeukemiaScience Translational Medicine, 2011